Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

A method of combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity in a HER2-positive cancer patient population, comprising administering Pertuzumab, Trastuzumab, and chemotherapy to the patients in the population.

An article of manufacture comprising a vial with Pertuzumab therein and a package insert, wherein the package insert provides the safety data in Table 3 or Table 4.

A method for making an article of manufacture comprising packaging together a vial with Pertuzumab therein and a package insert, wherein the package insert provides the safety data in Table 3 or Table 4.

A method of ensuring safe and effective use of Pertuzumab comprising packaging together a vial with Pertuzumab therein and a package insert, wherein the package insert provides the safety data in Table 3 or Table 4 and the efficacy data in Table 2, Table 5, FIG. 8, or FIG. 10.

A method of treating early-stage HER2-positive breast cancer comprising administering Pertuzumab, Trastuzumab, and chemotherapy to a patient with the breast cancer, wherein the chemotherapy comprises anthracycline-based chemotherapy, or carboplatin-based chemotherapy.

A method of treating HER2-positive cancer in a patient comprising co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag to the patient.

An intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.

A method of treating HER2-positive gastric cancer in a human subject comprising administering Pertuzumab, Trastuzumab, and chemotherapy to the subject with HER2-positive gastric cancer.

A method of treating gastric cancer in a human subject comprising administering Pertuzumab to the subject with gastric cancer, wherein Pertuzumab is administered at a dose of 840 mg in all treatment cycles.

A method of treating HER2-positive non-resectable or metastatic adenocarcinoma of the stomach or gastroesophageal junction in a human patient who did not receive prior chemotherapy for metastatic disease, except prior adjuvant or neoadjuvant therapy completed more than six months before the current treatment, comprising administering Pertuzumab, Trastuzumab, cisplatin, and capecitabine or fluorouracil (5-FU) to the patient in an amount to improve progression free survival (PFS) and/or overall survival (OS), wherein the patient has an Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) of 0-1.

A method of improving progression free survival (PFS) in a human patient with HER2-positive non-resectable or metastatic adenocarcinoma of the stomach or gastroesophageal junction comprising administering Pertuzumab to the patient in combination with Trastuzumab and chemotherapy.

A method of treating HER2-positive breast cancer in a patient comprising administering Pertuzumab, Trastuzumab and vinorelbine to the patient.

A method of treating HER2-positive breast cancer in a patient comprising administering Pertuzumab, Trastuzumab, and aromatase inhibitor to the patient.

A method of treating a cancer patient comprising administering to the patient an initial dose of 840 mg of Pertuzumab followed every 3 weeks thereafter by a dose of 420 mg of Pertuzumab, and further comprising re-administering an 840 mg dose of Pertuzumab to the patient if the time between two sequential 420 mg doses is 6 weeks or more.

A method for treating HER2-positive metastatic or locally recurrent breast cancer in a patient comprising administering Pertuzumab, Trastuzumab and taxoid to the patient, wherein the patient has been previously treated with a Trastuzumab and/or lapatinib as adjuvant or neoadjuvant therapy.

A method for treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer in a patient comprising administering Pertuzumab and chemotherapy to the patient, wherein the low HER3 cancer expresses HER3 mRNA at a concentration ratio equal or lower than about 2.81 as assessed by polymerase chain reaction (PCR).